Peer Reviewed Publications

For citations, please hit Google Scholar

2026

39. Prospective Breast Cancer Biomarkers Identified Using miR-526b-Driven Metabolic Alterations. Nault B, Majumder M. Cancer Informatics (Sage Journals). January 18, 2026; volume 25. https://doi.org/10.1177/11769351251408670

2025

38. Investigating the effects of miR-526b and miR-655 on doxorubicin sensitivity in breast cancer. Reid M. Opperman, Sujit Maiti and Majumder M. Scientific Reports (Springer Nature); September 29, 2025; 15, Article number: 33584 (2025); https://doi.org/10.1038/s41598-025-18719-y.

37. Distinct Oxidative Stress Adaptations Driven by the Overexpression of miR-526b,miR-655, and COX-2 in Breast Cancer. Reid M. Opperman, Sujit Maiti and Majumder M. International Journal of Molecular Sciences (MDPI); September 18, 2025; 2025, 26(18), 9103; https://doi.org/10.3390/ijms26189103.

36. miR-526b enhances glucose metabolism in breast cancer cells, an effect reversed by targeting the COX-2/EP4 pathway. Braydon D. Nault, Majumder M. Molecular Biology Reports (Springer Nature); April 01, 2025; Volume 52, article number 351, (2025); https://doi.org/10.1007/s11033-025-10430-5.

2024

35. A Prospective Tumour Marker for Breast Cancer: YWHAB and Its Role in Promoting Oncogenic Phenotypes. Gopaul VL, Winstone L, Gatien BG, Nault BD, Maiti S, Opperman RM, Majumder M.; Breast Cancer: Targets and Therapy (Dovepress Taylor & Francis Group); December 14, 2024; Volume 2024:16 Pages 935—956; https://doi.org/10.2147/BCTT.S479384.

34. miR-526b dysregulates glucose metabolism via the COX2/EP4 pathway. Braydon D Nault and Majumder M.; Jun 10, 2024; Preprint. Research Square; DOI:https://doi.org/10.21203/rs.3.rs-4510975/v1.

33. Investigating the Roles of YWHAB in Breast Cancer. Lacey Winstone^†, Beatrice G Gatien^†, Vaishnavi L Gopaul^†, Braydon D Nault, Maiti Sujit, Reid M Opperman, Majumder M. [^†,equal contribution]; Mar 29, 2024; Preprint. Research Square; DOI:https://doi.org/10.21203/rs.3.rs-4139025/v1.

2023

32. Breast cancer cell secretome analysis to decipher miRNA regulating the tumor microenvironment and discover potential biomarkers. Riley Feser, Reid Opperman, Braydon Nault, Sujit Maiti, Vincent Chen, Majumder M. Heliyon (Cell Press); April 14, 2023; e15421, Volume 9, Issue 4; https://doi.org/10.1016/j.heliyon.2023.e15421.

2022

31. Breast Cancer Cell Secretome Analysis to Decipher miRNA Tumor Biology and Discover Potential Biomarkers. Riley Feser, Reid Opperman, Braydon Nault, Sujit Maiti, Vincent Chen, Majumder M. Feb 07, 2022; Preprint. Research Square; DOI:https://doi.org/10.21203/rs.3.rs-1328838/v1.

30. Handbook of Oxidative Stress in Cancer: Therapeutic Aspects. Riley Feser, Reid Morgan Opperman, Sujit Maiti, and Majumder M. Therapeutic Aspects (Springer Nature); January 20, 2022; https://doi.org/10.1007/978-981-16-1247-3_239-1.

2021

29. Pri-miR526b and Pri-miR655 Are Potential Blood Biomarkers for Breast Cancer. Majumder M., Kingsley Chukwunonso Ugwuagbo, Sujit Maiti, Peeyush K Lala, Muriel Brackstone. Cancers (MDPI); July 30, 2021; 2021, 13(15),3838; https://doi.org/10.3390/cancers13153838.

28. Prostaglandin E2 Receptor 4 (EP4) as a Therapeutic Target to Impede Breast Cancer-Associated Angiogenesis and Lymphangiogenesis. De Paz Linares G.A.^†, Opperman R.M.^†, Majumder M, Lala P.K.[^†,equal contribution]; Cancers (MDPI); February 19, 2021; 2021, 13, 942; https://doi.org/10.3390/cancers13050942.

2020

27. Chemically Induced Hypoxia Enhances miRNA Functions in Breast Cancer. Gervin E^†, Shin B^†, Opperman R^‡, Cullen M^‡, Freser R^‡, Maiti S, Majumder M. [^†,^‡equal contribution]; Cancers(MDPI); July 22, 2020; 2020, 12(8), 2008; https://doi.org/10.3390/cancers12082008.

2019

26. miR526b andmiR655 Induce Oxidative Stress in Breast Cancer. Shin B, Freser R, Nault B, Hunter S, Maiti S, Ugwuagbo KC, Majumder M.; International Journal of Molecular Sciences (MDPI); August 19, 2019; 2019 Aug 19;20(16); https://doi.org/10.3390/ijms20164039.

25. Mir526b and Mir655 Promote Tumour Associated Angiogenesis and Lymphangiogenesis in Breast Cancer. Hunter S, Nault B#, Ugwuagbo KC#, Maiti S, Majumder M. [# equal contribution]; Cancers (MDPI); July 04, 2019; 2019, 11(7), 938; https://doi.org/10.3390/cancers11070938.

24. Tumor suppressor role of cytoplasmic polyadenylation element binding protein 2 (CPEB2) in human mammary epithelial cells. Tordjman J#, Majumder M.#, Amiri M, Hasan A, Hess D, Lala PK [# equal contribution first authors]; BMC Cancer (Springer Nature); June 11, 2019; 19, Article number: 561 (2019); https://doi.org/10.1186/s12885-019-5771-5.

23. Prostaglandin E2 Promotes Embryonic Vascular Development and Maturation in Zebrafish. Kingsley Chukwunonso Ugwuagbo, Sujit Maiti, Ahmed Omar, Stephanie Hunter^*, Braydon Nault^*, Caleb Northam, Majumder M. [*authors contributed equally]; Biology Open (The Company of Biologists); April 18, 2019; (2019) 8 (4): bio039768; https://doi.org/10.1242/bio.039768.

2018

22. Roles of prostaglandins in tumor-associated lymphangiogenesis with special reference to breast cancer. Lala PK, Nandi P, Majumder M.; Cancer Metastasis Review (Springer Nature); June 01, 2018; Volume 37, pages 369–384, (2018); https://doi.org/10.1007/s10555-018-9734-0.

21. EP4 as a Therapeutic Target for Aggressive Human Breast Cancer; Majumder M, Nandi P, Omar A, Ugwuagbo KC, Lala PK; International Journal of Molecular Sciences (MDPI). March 29, 2018; 2018, 19(4), 1019; https://doi.org/10.3390/ijms19041019.

20. COX-2 induces oncogenic micro RNA miR655 in human breast cancer. Majumder M, Dunn L, Liu L, Hasan A, Vincent K, Brackstone M, Hess D, Lala PK; Scientific Report (Springer Nature); January 10, 2018; 8, Article number: 327 (2018); https://doi.org/10.1038/s41598-017-18612-3.

2017

19. PGE2 promotes breast cancer-associated lymphangiogenesis by activation of EP4 receptor on lymphatic endothelial cells. Nandi P, Girish GV, Majumder M., Xin X, Tutunea-Fatan E, Lala PK.; BMC Cancer (Springer Nature); January 05, 2017; 17, Article number: 11 (2017); https://doi.org/10.1186/s12885-016-3018-2.

2016

18. COX-2 Induces Breast Cancer Stem Cells via EP4/PI3K/AKT/NOTCH/WNT Axis. Majumder M., Xin X, Liu L, Tutunea-Fatan E, Rodriguez-Torres M, Vincent K, Postovit LM, Hess D, Lala PK.; Stem Cells (Oxford Academic); June 27, 2016; Volume 34, Issue 9, Pages 2290–2305; https://doi.org/10.1002/stem.2426.

2015

17.Sequence and expression variations in 23 genes involved in mitochondrial and non-mitochondrial apoptotic pathways and risk of oral leukoplakia and cancer. Datta S, Ray A, Singh R, Mondal P, Basu A, De Sarkar N, Majumder M., Maiti G, Baral A, Jha GN, Mukhopadhyay I, Panda C, Chowdhury S, Ghosh S, Roychoudhury S, Roy B. Mitochondrion (ScienceDirect); September 21, 2015; 2015 Nov;25:28-33; https://doi.org/10.1016/j.mito.2015.09.001.

16. The role of CCL21/CCR7 chemokine axis in breast cancer-induced lymphangiogenesis.Tutunea-Fatan E, Majumder M., Xin X, Lala PK. Molecular Cancer (BMC Springer Nature); February 10, 2015; 2015 Feb 10;14:35; https://doi.org/10.1186/s12943-015-0306-4.

15.COX-2 Elevates Oncogenic miR-526b in Breast Cancer by EP4 Activation. Majumder M., Landman E, Liu L, Hess D, Lala PK. Molecular Cancer Research (AACR); June 01, 2015; 2015 Jun;13(6):1022-33; https://doi.org/10.1158/1541-7786.MCR-14-0543.

2014

14. D-loop somatic mutations and ∼5 kb “common” deletion in mitochondrial DNA: important molecular markers to distinguish oral precancer and cancer. Datta S, Chattopadhyay E, Ray JG, Majumder M., Roy PD, Roy B. Tumour Biology (Springer Nature); December 20, 2014; 2015 Apr;36(4):3025-33; https://doi.org/10.1007/s13277-014-2937-2.

13. Prostaglandin E2 receptor EP4 as the common target on cancer cells and macrophages to abolish angiogenesis, lymphangiogenesis, metastasis, and stem-like cell functions. Majumder M., Xin X, Liu L, Girish GV, Lala PK. Cancer Science (Wiley Online Library); June 30, 2014; 2014 Sep;105(9):1142-51. https://doi.org/10.1111/cas.12475.

2013

12. Single nucleotide polymorphism network: a combinatorial paradigm for risk prediction. Das Roy P, Sengupta D, Dasgupta AK, Kundu S, Chaudhuri U, Thakur I, Guha P, Majumder M., Roy R, Roy B. PLoS One; September 11, 2013; 2013 Sep 11;8(9):e74067; https://doi.org/10.1371/journal.pone.0074067.

11. A practical and sensitive method of quantitating lymphangiogenesis in vivo. Majumder M., Xin X, Lala PK. Laboratory Investigation (ELSEVIER); May 27, 2013; 2013 Jul;93(7):779-91; https://doi.org/10.1038/labinvest.2013.72.

2012

10. Association between polymorphisms at N-acetyltransferase 1 (NAT1) & risk of oral leukoplakia & cancer. Majumder M., Ghosh S, Roy B. Indian J Med Res; October 2012; 136(4):605-13; PMID: 23168701; PMCID: PMC3516028.

9.Differential haplotype amplification leads to misgenotyping of heterozygote as homozygote when using single nucleotide mismatch primer. De Sarkar N, Majumder M., Roy B. Electrophoresis (Wiley Analytical Science); September 26, 2012; 33(23):3564-73. 2012 Dec; https://doi.org/10.1002/elps.201200363.

8.Targeting COX-2 and EP4 to control tumor growth, angiogenesis, lymphangiogenesis and metastasis to the lungs and lymph nodes in a breast cancer model. Xin X, Majumder M., Girish GV, Mohindra V, Maruyama T, Lala PK. Laboratory Investigation (ScienceDirect); August 2012; 92(8):1115-28; https://doi.org/10.1038/labinvest.2012.90.

7. Co-expression of α9β1 integrin and VEGF-D confers lymphatic metastatic ability to a human breast cancer cell line MDA-MB-468LN. Majumder M., Tutunea-Fatan E, Xin X, Rodriguez-Torres M, Torres-Garcia J, Wiebe R, Timoshenko AV, Bhattacharjee RN, Chambers AF, Lala PK. PLoS One; Apr 24, 2012; 2012;7(4):e35094; https://doi.org/10.1371/journal.pone.0035094.

2009

6.Polymorphisms at p53, p73, and MDM2 loci modulate the risk of tobacco associated leukoplakia and oral cancer. Misra C, Majumder M., Bajaj S, Ghosh S, Roy B, Roychoudhury S. Molecular Carcinogenesis (Wiley Online Library). February 09, 2009; 48(9):790-800; https://doi.org/10.1002/mc.20523.

5.Variant haplotypes at XRCC1 and risk of oral leukoplakia in HPV non-infected samples. Majumder M., Indra D, Roy PD, Datta S, Ray JG, Panda CK, Roy B. Journal of Oral Pathology & Medicine (Wiley Online Library). January 19, 2009; 38(2):174-80; https://doi.org/10.1111/j.1600-0714.2008.00690.x.

2008

4. Pharmacogenomics of Anti-TB Drugs-Related HepatotoxicityRoy PD, Majumder M., Roy B. Pharmacogenomics (Taylor & Francis online); February 27, 2008; 9(3):311-21. https://doi.org/10.2217/14622416.9.3.311.

2007

3.Increased risk of oral cancer in relation to common Indian mitochondrial polymorphisms and Autosomal GSTP1 locus. Datta S, Majumder M., Biswas NK, Sikdar N, Roy B. Cancer (American Cancer Society); November 1, 2007; https://doi.org/10.1002/cncr.23016.

2.Polymorphisms at XPD and XRCC1 DNA repair loci and increased risk of oral leukoplakia and cancer among NAT2 slow acetylators. Majumder M., Sikdar N, Ghosh S, Roy B. International Journal of Cancer (Wiley Online Library); May 15, 2007; 120(10):2148-56; https://doi.org/10.1002/ijc.22547.

2005

1.Increased risk of oral leukoplakia and cancer among mixed tobacco users carrying XRCC1 variant haplotypes and cancer among smokers carrying two risk genotypes: one on each of two loci, GSTM3 and XRCC1 (Codon 280). Majumder M., Sikdar N, Paul RR, Roy B. Cancer Epidemiology Biomarkers and Prevention (AACR); September 19, 2005; 14(9):2106-12; https://doi.org/10.1158/1055-9965.EPI-05-0108.

Brandon University